These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 22987730)
1. Marking the markers of Alzheimer's: too good to diagnose, too bad to use? Olah Z; Pakaski M; Janka Z; Kalman J Neuropsychopharmacol Hung; 2012 Sep; 14(3):165-76. PubMed ID: 22987730 [TBL] [Abstract][Full Text] [Related]
2. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease. Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737 [TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. Marksteiner J; Hinterhuber H; Humpel C Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711 [TBL] [Abstract][Full Text] [Related]
4. Genetic and biochemical markers for Alzheimer's disease: recent developments. Mulder C; Scheltens P; Visser JJ; van Kamp GJ; Schutgens RB Ann Clin Biochem; 2000 Sep; 37 ( Pt 5)():593-607. PubMed ID: 11026514 [No Abstract] [Full Text] [Related]
5. Association between EEG abnormalities and CSF biomarkers in a memory clinic cohort. Kramberger MG; Kåreholt I; Andersson T; Winblad B; Eriksdotter M; Jelic V Dement Geriatr Cogn Disord; 2013; 36(5-6):319-28. PubMed ID: 24022277 [TBL] [Abstract][Full Text] [Related]
6. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902 [TBL] [Abstract][Full Text] [Related]
7. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Blennow K; Zetterberg H Med Clin North Am; 2013 May; 97(3):369-76. PubMed ID: 23642576 [TBL] [Abstract][Full Text] [Related]
8. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543 [TBL] [Abstract][Full Text] [Related]
11. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
13. Clinical, biological, and imaging features of monogenic Alzheimer's Disease. Pilotto A; Padovani A; Borroni B Biomed Res Int; 2013; 2013():689591. PubMed ID: 24377094 [TBL] [Abstract][Full Text] [Related]
14. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Prvulovic D; Hampel H Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022 [TBL] [Abstract][Full Text] [Related]